Latest news with #BIRAC
Business Upturn
08-08-2025
- Business
- Business Upturn
Specialty Enzymes Market to Reach $9.2 Billion by 2029, Driven by Biotech Innovation and Public Funding
Delray Beach, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) — According to a research report published by MarketsandMarkets, 'Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Proteases, Lipases, Polymerases & Nucleases), Application (Pharmaceuticals, Diagnostics, Research & Biotechnology), Form & Region – Global Forecast to 2029'. Specialty Enzymes Market Size & Growth 2029 Market Size: $9.2 billion 2024 Forecast: $6.1 billion Forecast CAGR (2024 – 2029): 8.5% Top Segments: Source, Type, Application, Region Leading Applications: Pharmaceuticals, Diagnostics, Research & Biotechnology The specialty enzymes market is on an accelerated growth path, propelled by public funding, expanding pharmaceutical demand, and rising applications in diagnostics and industrial processing. From funding initiatives like India's BIG scheme to booming protease demand and regional momentum in Asia Pacific, several forces are reshaping the future of enzyme technology. Learn more by downloading the PDF copy! Supportive Government Policies and Funding Drive Innovation Governments across the globe are playing a pivotal role in driving biotechnological advancements through funding and incentives. These measures not only foster R&D but also promote the commercialization of innovative enzyme-based solutions across industries. European Union : The Horizon Europe program, with a staggering USD 103.6 billion budget for 2021–2027, places biotechnology at the heart of its research agenda. This commitment bolsters the development of cutting-edge enzyme applications for medical, agricultural, and industrial sectors. : The Horizon Europe program, with a staggering USD 103.6 billion budget for 2021–2027, places biotechnology at the heart of its research agenda. This commitment bolsters the development of cutting-edge enzyme applications for medical, agricultural, and industrial sectors. United States : The NIH allocated over USD 42.0 billion in 2022 for biomedical research. A portion of this investment is earmarked for biotech projects, including the creation of novel enzymes for therapeutic and industrial use. : The NIH allocated over USD 42.0 billion in 2022 for biomedical research. A portion of this investment is earmarked for biotech projects, including the creation of novel enzymes for therapeutic and industrial use. India: The Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology, is actively fueling innovation via programs like the Biotechnology Ignition Grant (BIG). In 2020, BIRAC dedicated Rs. 50 crores (~USD 6.7 million) to support around 100 biotech startups, helping develop enzyme-based solutions across pharmaceuticals and diagnostics. These initiatives are not only pushing the boundaries of enzyme technology but are also helping smaller players scale and commercialize faster. Asia Pacific Dominates the Specialty Enzymes Landscape Asia Pacific holds the largest specialty enzymes market share. The region's dominance is driven by a robust pharmaceutical and biotechnology ecosystem, with countries like India leading the charge. India, contributing over 20% to the global generics supply, is a major consumer of specialty enzymes for drug manufacturing. Its rapid expansion in biopharma, combined with a strong base of enzyme producers and government support, positions it as a critical growth hub for the industry. Protease Enzymes: Fastest Growing Segment Among the various enzyme types, proteases are emerging as the fastest-growing category. These enzymes play a crucial role in drug formulation and therapeutic protein production—vital in treating chronic diseases such as cancer, diabetes, and autoimmune disorders. Their importance extends to biotechnology, where they are used for protein engineering and modification. Proteases allow precise protein cleavage, making them essential in developing innovative biologics. Companies like Novo Nordisk rely on proteases for efficient insulin production, showcasing their relevance in meeting growing global health demands. Animal-Sourced Enzymes Continue to Hold Strong Market Share Enzymes derived from animal sources retain a significant presence in the specialty enzymes market, especially due to their high specificity and activity. Pharmaceuticals : Pancreatic enzymes like trypsin and chymotrypsin are used in drug development, particularly for biologics. : Pancreatic enzymes like trypsin and chymotrypsin are used in drug development, particularly for biologics. Diagnostics : Enzymes such as lactase and thrombin are vital in clinical testing and surgical procedures. : Enzymes such as lactase and thrombin are vital in clinical testing and surgical procedures. Food Industry: Enzymes like rennet remain essential for applications such as cheese production. Their efficiency and reliability across such diverse applications make animal-sourced enzymes indispensable to both legacy and emerging industries. Industry Update: Production Expansion and Quality Focus In March 2024, Biocatalysts, a BRAIN Biotech Group company, expanded its Cardiff facility with a large-scale freeze-drying plant. The site now offers custom enzyme solutions for food, beverage, and life sciences sectors while complying with kosher, halal, ISO9001:2015, and FSSC22000 standards—ensuring top-tier quality and regulatory alignment. Leading Players in the Specialty Enzymes Market Key specialty enzymes companies shaping the future of the specialty enzymes market include: BRAIN Biotech AG (Germany) Novozymes A/S (Denmark) Codexis, Inc. (US) Sanofi (France) Merck KGaA (Germany) Dyadic International Inc (US) Advanced Enzyme Technologies (India) Amano Enzyme Inc (Japan) F. Hoffmann-La Roche Ltd (Switzerland) New England Biolabs (US) BBI Solutions (UK) Creative Enzymes (US) Bioseutica (Netherlands) SEKISUI Diagnostics (US) These players are investing heavily in R&D, expanding production capabilities, and exploring strategic partnerships to stay competitive in a rapidly evolving market. Looking to identify growth opportunities, market adjacencies, or key partnerships in the specialty enzymes space? Speak to an analyst today and get a tailored roadmap for innovation and investment. Explore Adjacent Markets Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Standard
10-07-2025
- Business
- Business Standard
ATGC Biotech Recognised with Innovation Leadership Award 2025 for Transforming Crop Protection through Deep-Tech Innovation
VMPL New Delhi [India], July 10: In a defining moment for Indian agri-innovation, ATGC Biotech Pvt. Ltd. was awarded the Innovation Leadership Award 2025 by Shri Piyush Goyal, Hon'ble Union Minister of Commerce and Industry, during the prestigious 16th Agriculture Leadership Conclave organized by Agriculture Today in New Delhi today. The Agriculture Leadership Award 2025 was presented to ATGC Biotech for Innovation Leadership in sustainable pest management with cutting edge pheromone technologies. The award was selected by the National Awards Committee, under the Chairmanship of Former Chief Justice of India, Justice P. Sathasivam, recognizing ATGC's pioneering role in IP-led, BioE3-aligned biomanufacturing--a transformative leap toward ultra-low-dose, waterless, and residue-free crop protection powered by synthetic biology and material science. With 26 patents, and 50+ commercial-stage products ATGC is driving India's emergence as a global biotechnology powerhouse and a BioE3-compliant leader in climate-resilient agriculture. With strategic R & D support from BIRAC and the Department of Science and Technology (DST), ATGC is powering India's transition from volume-based agrochemicals to precision, carbon-smart crop protection. On receiving the award, Dr. Markandeya Gorantla, Chairman & Managing Director, and Dr. V.B. Reddy, Executive Director, of ATGC Biotech said, "This award is a celebration of Indian science and its capacity to lead with purpose. We thank Agriculture Today for honoring deep-tech innovation, and express our sincere gratitude to BIRAC, DBT, and DST for enabling our platform to go from bench to field, from grams to global." They further added, "This recognition reinforces the critical role of agri-innovation in advancing India's strategic priorities--where food security, climate resilience, and global competitiveness converge through science and sustainability." For over a century, agriculture has leaned on chemical-based solutions to secure food systems. Today, ATGC adds a new layer of intelligence--shifting from reaction to prevention, from control to communication. ATGC has developed innovative solutions like CREMIT PBW and Akarsh ME, deployed across 200,000+ acres, cutting down chemical sprays and water use while decarbonizing the agri-supply chain. CREMIT PBW empowers cotton farmers with a sustainable, pesticide-free approach to managing pink bollworm, while Akarsh ME offers fruit growers an eco-friendly, highly effective solution for fruit fly control ensuring maggot-free harvests and residue-free fruits. ATGC's core promise is to safeguard crops using just grams of active ingredient per acre per month, with no water and minimal application. It's a new paradigm. A smarter, scalable solution for a climate-conscious world. In 2024, the World Economic Forum highlighted ATGC as a global case study for scaling pheromone tech in row crops like rice and cotton. The company is the only non-US supplier to USDA's "Slow the Spread" program, with 44 new molecules under registration across 20+ countries. About ATGC Pvt Ltd. Founded in 2011 and headquartered in Genome Valley, Hyderabad, ATGC is India's only commercial-scale manufacturer of pheromone biosimilars. With a mission to create a greener, healthier planet, ATGC offers high-quality insect pheromones, semiochemicals, and advanced IPM technologies that effectively manage pest populations while minimizing the use of harmful chemical pesticides. ATGC's flagship product, CREMIT PBW, Akarsh ME has been deployed across more than 200,000 acres of cotton and horticulture crops in India, enabling residue-free, export-compliant farming and reducing dependency on conventional spray cycles At ATGC, we are committed to supporting farmers with the latest pheromone-based applications and groundbreaking solutions that drive the future of agriculture. Our innovations are designed to protect crops, improve yields, and promote eco-friendly farming practices, ensuring both the well-being of farmers and the environment For more information:
Hans India
08-07-2025
- Business
- Hans India
India targets $300 bn bioeconomy by 2030
New Delhi: The government is committed to realising a $300 billion bioeconomy by 2030, reiterated Union Minister of Science and Technology, Dr. Jitendra Singh on World Bioproduct Day on Monday. Calling for a wider public understanding and inclusive participation in India's biotechnology mission, Singh stated that every Indian was a stakeholder in the country's bioeconomy. The biotechnology ecosystem in the country 'has grown from just around 50 startups a decade ago to nearly 11,000 today -- a leap made possible by policy backing and institutional partnerships,' said Singh, while speaking at an event, organised by the Department of Biotechnology (DBT) and its agencies BIRAC and iBRIC+. Referring to the recently launched BioE3 Policy, Singh noted that it laid the groundwork for India to lead in sustainable biomanufacturing by aligning bioeconomy goals with environmental sustainability, economic growth, and equity. The BioE3 (Biotechnology for Economy, Environment and Employment) Policy aims to position India as a global leader in bio-based innovations. 'Bioproducts aren't limited to laboratories anymore. They're about livelihoods -- from biodegradable packaging to eco-friendly personal care, from rural employment to green jobs,' he said. He emphasised that the future industrial revolution will be driven by bioeconomy, and India, he believes, has taken the lead. Further, acknowledging the challenges faced by young scholars in biotech, the Minister pointed out the mismatch between parental expectations and individual aptitude in career choices. He termed the National Education Policy (NEP) 2020 a 'game-changer' that would allow students to pursue disciplines of interest with flexibility. 'We are seeing a new generation with real aptitude and capacity to learn,' he said. Singh also urged for stronger social media outreach, using success stories, local languages, and relatable formats to communicate biotech's relevance to common citizens. 'If we want to attract young talent, we must link biotechnology to profitability and livelihood, not just academics,' he said. Meanwhile, Secretary, DBT and Chairman of BIRAC, Dr. Rajesh S. Gokhale outlined steps being taken to operationalise the BioE3 Policy in the country. These include 'support for pilot manufacturing, region-specific innovation missions, and strengthening the pipeline from research to market,' Gokhale said.
Hans India
24-06-2025
- Business
- Hans India
Biotech breakthrough: UoH alumni launch strategic partnership
Hyderabad: In a significant achievement for alumni-led biotech investment and translational entrepreneurship, Dr Uday Saxena and Dr Markandeya Gorantla, graduates of the University of Hyderabad, have signed a term sheet to fund Utopia Therapeutics Pvt Ltd, an early-stage deep-tech startup. This important announcement was made at the BIO International Convention 2025, held in Boston on June 19. The Whale Tank Biocatalyst Fund, which collaborates with the Federation of Asian Biotech Associations (FABA) as a knowledge partner and is supported by Prof. Reddanna Pallu and Dr. Ratnakar Palakodeti, highlights the impactful contributions of University of Hyderabad alumni Dr. Saxena and Dr. Gorantla to the global biotech landscape. The signing event was attended by Dr. Jitendra Kumar, Managing Director of BIRAC, along with key leaders from ABLE and the Department of Biotechnology (DBT). The Whale Tank Biocatalyst Fund is set to commit over USD 1.5 million in total support to Utopia Therapeutics. This vital funding will advance the development of Utopia's lead asset, UT009, a first-in-class vaccine designed to combat obesity and Non-Alcoholic Fatty Liver Disease (NAFLD). Additionally, the investment will strengthen Utopia's pipeline of UT18-based regenerative health products, enhancing infrastructure, manufacturing capabilities, and go-to-market strategies. Dr. Jitendra Kumar, MD of BIRAC, stated, 'This partnership reflects the strength of India's translational biotech ecosystem. A vaccine for metabolic disorders and a regenerative product pipeline emerging from India and entering global markets demonstrate the scientific depth and entrepreneurial maturity that BIRAC has consistently supported. It's especially gratifying to witness this in my presence. I'm pleased to see that some of the companies now being funded by Whale Tank were previously supported by BIRAC. This is a great enabling system — we've always envisioned such investor-driven support for Indian deep-tech science.' Dr. Uday Saxena, Co-Founder of Utopia Therapeutics Pvt. Ltd., said, 'We were deeply impressed by Utopia's science and clarity of purpose. The UT18 platform has demonstrated multi-tissue regenerative potential, and with Whale Tank's support, we are investing not just in products but in a future of preventive and regenerative health.' This collaboration marks a significant milestone for India's evolving biotech investment landscape, as well as for innovative product discovery and development. It exemplifies how scientific innovation, strategic capital, and experienced mentorship from institutions like the University of Hyderabad can converge through a national innovation pipeline with global ambitions. Co-founded by University of Hyderabad alumni Dr. Uday Saxena and Dr. Markandeya Gorantla, with FABA as a knowledge partner, the Whale Tank Biocatalyst Fund focuses on identifying and investing in early-stage deep-tech startups in the biotech sector, fostering innovation, mentorship, and translational entrepreneurship. The Whale Tank Biocatalyst Fund's portfolio includes a diverse range of innovative companies, showcasing India's commitment to bio-strategic sovereignty and investment in critical areas for human and environmental health.
The Hindu
19-06-2025
- Business
- The Hindu
Miltenyi Biotec, BIRAC partner to boost cell and gene therapy capabilities
Miltenyi Biotec India and Biotechnology Industry Research Assistance Council (BIRAC) have signed a letter of intent for a collaboration aimed at enhancing India's capabilities in cell and gene therapy through capacity building, advancing clinical research and to solve unmet medical needs by local manufacturing of cell therapies. The LOI was signed at the BIO International Convention 2025, which opened this week in Boston, they said in a joint release on Wednesday. German cellular research, cell therapy and cell manufacturing solutions provider Miltenyi Biotec in February had announced plans for a cell and gene therapy centre of excellence in Hyderabad. The partnership with BIRAC is to build national capabilities and upskill scientific talent by implementing structured training and capacity-building programmes for clinicians, researchers and technicians in CGT manufacturing, analytics, and quality control. It is also to expand translational research efforts through co-development of academic and multi-centre studies and set up point-of-care (PoC) CAR-T centres across India using automated manufacturing platforms to enable cost-effective and scalable access to personalised CGT treatments. Their partnership with also promote targeted cell therapy research and support local innovation through the identification and mentoring of Indian startups thus aligning with the Make in India mission by enhancing domestic production of critical and manufacturing components and by supporting development of national CGT COEs. 'Together, we are exploring how to address current unmet needs in medical science, particularly in areas like autoimmune and rare diseases by enhancing access through innovative mechanisms such as point-of-care CAR-T and graft engineering,' MiltenyiBiotec India MD Priya Kapoor-Hingorani said.
